Abstract
Artificial intelligence (AI) systems leveraging speech and language changes could support timely detection of Alzheimer's disease (AD). The AMYPRED study (NCT04828122) recruited 133 subjects with an established amyloid beta (Aβ) biomarker (66 Aβ+, 67 Aβ-) and clinical status (71 cognitively unimpaired [CU], 62 mild cognitive impairment [MCI] or mild AD). Daily story recall tasks were administered via smartphones and analyzed with an AI system to predict MCI/mild AD and Aβ positivity. Eighty-six percent of participants (115/133) completed remote assessments. The AI system predicted MCI/mild AD (area under the curve [AUC]=0.85, ±0.07) but not Aβ (AUC=0.62±0.11) in the full sample, and predicted Aβ in clinical subsamples (MCI/mild AD: AUC=0.78 ±0.14; CU: AUC=0.74 ±0.13) on short story variants (immediate recall). Long stories and delayed retellings delivered broadly similar results. Speech-based testing offers simple and accessible screening for early-stage AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
